Menin inhibitor clinical trial puts pediatric leukemia patient in remission

“Patient response to revumenib has been good in other clinical trials,” explains Cuglievan. “But it’s also been short-lived when used alone. We thought we could do better. So, we combined it with two other drugs. And we’ve gotten such good results, this may well become the new standard of care.” 

Read more: https://www.mdanderson.org/cancerwise/menin-inhibitor-clinical-trial-puts-pediatric-leukemia-patient-in-remission.h00-159703068.html